Infliximab Reverses Peripheral CD4+ T Cell Depletion in Lymphopenic Sarcoidosis Patients.

Infliximab therapy modulates an antigen-specific immune response in chronic beryllium disease

“…Similar to our findings, in sarcoidosis subjects treated with infliximab there was a reversal of lymphopenia and increase in peripheral blood CD4 + T cells. 19 The mechanism by which infliximab affects cell counts in the blood and BAL is unknown. In rheumatoid arthritis (RA), infliximab treatment appeared to reverse a dysfunctional blood T reg cell population, with increase in the number and ability of the cells to suppress cytokine production.…”